Corcept Therapeutics Profit Margin

The latest profit margin for CORT is 6.57% as of June 2026. That compares with 18.5% in the prior-year period — down 64.5% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Corcept Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CORT's profit margin moved from 18.5% to 6.57% — a 64.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Corcept Therapeutics's valuation or profitability profile.

Against Healthcare companies, CORT currently prints 6.57% for profit margin, while the sector average sits near 9.48%. That is roughly 30.7% below the sector mean. Large gaps often invite a closer look at Corcept Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Corcept Therapeutics converts resources into returns. At 6.57%, CORT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 18.5% in the prior-year period — down 64.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CORT's profit margin (6.57%), review year-over-year change from 18.5%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.